Alexander van Akkooi, Chair of Melanoma Surgery at Melanoma Institute Australia, shared on LinkedIn:
“Latest editorial in Melanoma Research, discussing the latest data on the adjuvant individualized neoadjuvant treatment (INT) with the mRNA vaccine intismeran in combination with pembrolizumab.
Data presented by Prof. Georgina Long at the last ESMO – European Society for Medical Oncology meeting in Madrid and published in the NEJM recently. This editorial tries to address the position of the novel treatment within the field, ask questions and looks towards the future.
You can also read: